의약품 제제 시장 규모 조사 : 제형별, 적응증별, 최종 사용자별, 지역별 예측(2022-2032년)

Global demand for drug formulation is expected to increase at 5.6% CAGR over the forecast period from 2024 to 2032. The sales of the drug formulations market are estimated to reach a valuation of USD 1.67 trillion by 2023. Drug formulation is the meticulous process of designing and producing a medication in a specific form, such as tablets, capsules, liquids, or injections. This process involves the strategic combination of the active pharmaceutical ingredient (API) with other substances to create a stable, effective, and safe product. The primary objective is to ensure the drug's optimal absorption, distribution, metabolism, and excretion in the body. Applications of drug formulation encompass improving drug solubility, enhancing bioavailability, controlling release rates, and ensuring patient compliance. Effective formulation can also tackle issues like drug stability and taste, thereby making medications more accessible and acceptable to patients.

The pharmaceutical industry has witnessed a substantial revolution with the advent of novel technologies alongside more affordable and cost-effective manufacturing methods. Robotics and artificial intelligence are progressively being incorporated into the pharmaceutical industry to minimize production waste and downtime on the factory floor. Continuous advancements in personalized medicine have also paved the way for patient-centric models by unlocking numerous opportunities to address a wide range of medical conditions. Moreover, the escalating prevalence of chronic diseases among the population, coupled with rising investment flows in this sector, are driving market growth positively. The growing world population has significantly influenced the consumption of pharmaceuticals, thereby boosting the drug formulation industry recently. Consequently, the use of antidepressants doubled, the consumption of antihypertensive and antidiabetic medications almost doubled, and the intake of cholesterol-lowering medications nearly quadrupled between 2000 and 2015 in Organization for Economic Cooperation and Development (OECD) nations. A heightened focus on non-communicable diseases (NCDs), such as diabetes and hypertension, which are already prevalent in developed nations, persists while communicable diseases, such as Acquired Immunodeficiency Syndrome (AIDS), malaria, and tuberculosis, which affect many developing economies, continue to exist.

However, complexity in the supply chain stands as a restricting factor expected to hamper the drug formulation market growth. Most pharmaceutical companies grapple with a complex supply chain, which is either inefficient or under-utilized. The intricacy of the supply chain stems from low flexibility or its cost-effective nature. Nonetheless, increasing generic competition has dented the profitability of big players, and this trend is expected to persist over the years. Many pharmaceutical companies have commenced reorganizing their supply chain in response to evolving market structures, but these changes are primarily aimed at addressing short-term challenges. Alongside patent cliffs, the shortening of effective patent life poses a significant issue in the drug formulation market due to increasing time-to-market and stringent regulations.

The key regions considered for the global drug formulation market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is anticipated to hold the largest market share during the forecast period, attributed to the advanced healthcare infrastructure, significant investment in research and development, and the presence of major pharmaceutical companies. The Asia Pacific region is projected to witness the fastest growth, driven by the burgeoning pharmaceutical industry, improving healthcare infrastructure, and increasing prevalence of chronic diseases in countries such as China and India.

Major market players included in this report are:

• AstraZeneca plc.
• Bristol-Myers Squibb
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• 3M Company
• Bayer AG
• Teva Pharmaceuticals Industries Ltd.
• Amgen, Inc.

The detailed segments and sub-segment of the market are explained below:

By Dosage Form:

• Oral formulations
• Parenteral formulations
• Topical formulations
• Inhalation formulations

By Indication:

• Infectious Diseases
• Cancer
• Cardiovascular Diseases
• Diabetes
• Respiratory Diseases
• Central Nervous System Disorders
• Autoimmune Diseases
• Gastrointestinal Diseases
• Musculoskeletal Disorders
• Dermatological Disorders
• Other

By End User:

• Big pharma
• Small & Medium Size Pharma
• Biotech Companies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Drug Formulation Market Executive Summary

• 1.1. Global Drug Formulation Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Dosage Form
  • 1.3.2. By Indication
  • 1.3.3. By End User
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Drug Formulation Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Drug Formulation Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising prevalence of chronic diseases
  • 3.1.2. Technological advancements in drug formulation
  • 3.1.3. Increasing investment in pharmaceutical R&D
• 3.2. Market Challenges
  • 3.2.1. Complexity of supply chains
  • 3.2.2. Patent cliffs and shortened patent life
  • 3.2.3. Increasing generic competition
• 3.3. Market Opportunities
  • 3.3.1. Growth in personalized medicine
  • 3.3.2. Expansion in emerging markets
  • 3.3.3. Advances in biotechnology

Chapter 4. Global Drug Formulation Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Drug Formulation Market Size & Forecasts by Dosage Form 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Drug Formulation Market: Dosage Form Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Oral formulations
  • 5.2.2. Parenteral formulations
  • 5.2.3. Topical formulations
  • 5.2.4. Inhalation formulations

Chapter 6. Global Drug Formulation Market Size & Forecasts by Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Drug Formulation Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Infectious Diseases
  • 6.2.2. Cancer
  • 6.2.3. Cardiovascular Diseases
  • 6.2.4. Diabetes
  • 6.2.5. Respiratory Diseases
  • 6.2.6. Central Nervous System Disorders
  • 6.2.7. Autoimmune Diseases
  • 6.2.8. Gastrointestinal Diseases
  • 6.2.9. Musculoskeletal Disorders
  • 6.2.10. Dermatological Disorders
  • 6.2.11. Other

Chapter 7. Global Drug Formulation Market Size & Forecasts by End User 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Drug Formulation Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Big pharma
  • 7.2.2. Small & Medium Size Pharma
  • 7.2.3. Biotech Companies

Chapter 8. Global Drug Formulation Market Size & Forecasts by Region 2022-2032

• 8.1. North America Drug Formulation Market
  • 8.1.1. U.S. Drug Formulation Market
    • 8.1.1.1. Dosage Form breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Indication breakdown size & forecasts, 2022-2032
    • 8.1.1.3. End User breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Drug Formulation Market
• 8.2. Europe Drug Formulation Market
  • 8.2.1. U.K. Drug Formulation Market
  • 8.2.2. Germany Drug Formulation Market
  • 8.2.3. France Drug Formulation Market
  • 8.2.4. Spain Drug Formulation Market
  • 8.2.5. Italy Drug Formulation Market
  • 8.2.6. Rest of Europe Drug Formulation Market
• 8.3. Asia-Pacific Drug Formulation Market
  • 8.3.1. China Drug Formulation Market
  • 8.3.2. India Drug Formulation Market
  • 8.3.3. Japan Drug Formulation Market
  • 8.3.4. Australia Drug Formulation Market
  • 8.3.5. South Korea Drug Formulation Market
  • 8.3.6. Rest of Asia Pacific Drug Formulation Market
• 8.4. Latin America Drug Formulation Market
  • 8.4.1. Brazil Drug Formulation Market
  • 8.4.2. Mexico Drug Formulation Market
  • 8.4.3. Rest of Latin America Drug Formulation Market
• 8.5. Middle East & Africa Drug Formulation Market
  • 8.5.1. Saudi Arabia Drug Formulation Market
  • 8.5.2. South Africa Drug Formulation Market
  • 8.5.3. Rest of Middle East & Africa Drug Formulation Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. AstraZeneca plc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Bristol-Myers Squibb
  • 9.3.3. Eli Lilly and Company
  • 9.3.4. Gilead Sciences, Inc.
  • 9.3.5. Merck & Co., Inc.
  • 9.3.6. Novartis AG
  • 9.3.7. Pfizer Inc.
  • 9.3.8. AbbVie Inc.
  • 9.3.9. Boehringer Ingelheim International GmbH
  • 9.3.10. F. Hoffmann-La Roche AG
  • 9.3.11. Johnson & Johnson
  • 9.3.12. 3M Company
  • 9.3.13. Bayer AG
  • 9.3.14. Teva Pharmaceuticals Industries Ltd.
  • 9.3.15. Amgen, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes